共 50 条
- [1] BUDGET IMPACT ANALYSIS OF TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEMVALUE IN HEALTH, 2021, 24 : S96 - S97Holanda, P.Salgado De Santana, C.Senna, T.Carmo, L.Alexandre, R. F.
- [2] COST-EFFECTIVENESS ANALYSIS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN GREECEVALUE IN HEALTH, 2019, 22 : S619 - S620Vellopoulou, K.Stefanou, G.Tzanetakos, C.Boubouchairopoulou, N.Nakou, M.Kourlaba, G.
- [3] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN COLOMBIAINFLAMMATORY BOWEL DISEASES, 2022, 28 : S44 - S44Hansen, TawnyaMak, JoyceUnderwood, FoxWindsor, JosephKing, JamesQuan, JoshuaBuie, MichaelCoward, StephanieFrolkis, AlexLeung, AlexanderMa, ChristopherNovak, KerriPanaccione, RemoQian, YimingBurisch, JohanGearry, RichardNg, SiewKaplan, Gilaad
- [4] COST-EFFECTIVENESS OF TOFACITINIB FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE ULCERATIVE COLITIS IN COLOMBIAGASTROENTEROLOGY, 2022, 162 (03) : S44 - S44Gil, FabioJulian-Banos, FabianAmador, LuisaCastano, NataliaReyes, Juan
- [5] Cost-effectiveness of tofacitinib for the treatment of moderate to severe active ulcerative colitis in GreeceEUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2021, 33 (03) : 325 - 333Vellopoulou, KaterinaStefanou, GaryfalliaTzanetakos, CharalamposBoubouchairopoulou, NantiaNakou, MagdaliniGourzoulidis, GeorgeKourlaba, Georgia
- [6] COST-EFFECTIVENESS ANALYSIS OF TRANSTHYRETIN-ASSOCIATED AMYLOID CARDIOMYOPATHY FROM THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVEVALUE IN HEALTH, 2023, 26 (06) : S156 - S156Sebastiao, M.Ferreira, P.Senna, T.Alexandre, R. F.Almeida, P.
- [7] Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative ColitisAMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 (01) : 125 - 133Shaffer, Seth R.Huang, ElbertPatel, ShivaniRubin, David T.
- [8] BUDGETARY IMPACT OF INFLIXIMAB BIOSIMILAR IN THE TREATMENT OF PSORIASIS AND ULCERATIVE COLITIS IN THE PERSPECTIVE OF BRAZILIAN PUBLIC HEALTHCARE SYSTEMVALUE IN HEALTH, 2019, 22 : S49 - S50Alexandre, R. F.Salgado De Santana, C. F.Senna, T.
- [9] COST-EFFECTIVENESS OF 5-ASA THERAPY IN COMBINATION WITH BIOLOGICS OR TOFACITINIB IN THE TREATMENT OF ULCERATIVE COLITISGASTROENTEROLOGY, 2020, 158 (06) : S659 - S660Shaffer, SethHuang, ElbertPatel, ShivaniRubin, David T.
- [10] COST-EFFECTIVENESS ANALYSIS OF EMICIZUMAB VERSUS BYPASSING AGENTS IN PATIENTS WITH HEMOPHILIA A WITH INHIBITORS IN THE BRAZILIAN PUBLIC HEALTHCARE SYSTEM PERSPECTIVEVALUE IN HEALTH, 2019, 22 : S847 - S847Souza, P.Puopolo, G. R.Leme-Souza, R.